| abstract |
The present invention relates to new CGRP antagonists of the general formula (I), where U, V, X, Y, R1, R2 and R3 are defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of said salts, particularly the physiologically compatible salts thereof having inorganic or organic acids or bases, pharmaceuticals comprising said compounds, the use thereof, and method for the production thereof. |